Impact of STK11 copy loss on clinical outcomes to PD-(L)1 blockade in non–small cell lung cancer
Gutierrez, Catherine, Ricciuti, Biagio, Alessi, Joao Victor Machado, Pecci, Federica, Barrichello, Adriana Paula de Castro, Vaz, Victor R., Sholl, Lynette M., Awad, Mark M.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥ 50%) non–small cell lung cancer
Barrichello, Adriana Paula de Castro, Alessi, Joao Victor Machado, Ricciuti, Biagio, Pecci, Federica, Vaz, Victor R., Lamberti, Giuseppe, Turner, Madison M., Pfaff, Kathleen L., Rodig, Scott J., Awad, Mark M.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab
Ricciuti, Biagio, Elkrief, Arielle, Alessi, Joao Victor Machado, Wang, Xinan, Barrichello, Adriana Paula de Castro, Pecci, Federica, Lamberti, Giuseppe, Lindsay, James, Sharma, Bijaya, Felt, Kristen, Nishino, Mizuki, Sholl, Lynette M., Rodig, Scott J., Schoenfeld, Adam Jacob, Awad, Mark M.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC)
Ricciuti, Biagio, Alessi, Joao Victor Machado, Li, Yvonne Y., Vaz, Victor R., Pecci, Federica, Lamberti, Giuseppe, Barrichello, Adriana Paula de Castro, Gupta, Hersh, Nishino, Mizuki, Cherniack, Andrew D., Sholl, Lynette M., Rodig, Scott J., Awad, Mark M.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022)
Pecci, Federica, Ricciuti, Biagio, Alessi, Joao Victor Machado, Barrichello, Adriana Paula de Castro, Vaz, Victor R., Lamberti, Giuseppe, Lee, Jessica Kim, Schrock, Alexa Betzig, Goel, Vikas K, Zimmerman, Zach, Bahcall, Magda, Janne, Pasi A., Awad, Mark M.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Distinct genomic and immunophenotypic features of solid-predominant versus nonsolid-predominant stage I lung adenocarcinomas and association with disease recurrence after surgical resection
Alessi, Joao Victor Machado, Wei, Zihan, Ricciuti, Biagio, Vaz, Victor R., Barrichello, Adriana Paula de Castro, Lamberti, Giuseppe, Sharma, Bijaya, Pfaff, Kathleen L., Felt, Kristen, Turner, Madison M., Rodig, Scott J., Sholl, Lynette M., Awad, Mark M.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Differences in pathology and mutational status among colorectal cancer (CRC) patients pre-, post-, and during screening age
Fernandes, Gustavo Dos Santos, Pereira, Allan Andresson Lima, Braga, Gabriella Pereira, Gumz, Brenda Pires, Crosara Alves Texeira, Marcela, Mascarenhas, Cintia do Couto, Girardi, Daniel da Motta, Barrichello, Adriana Paula de Castro, Seidler, Heinrich
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article